SELLAS Life Sciences (SLS) Other financing activities (2010 - 2026)
SELLAS Life Sciences (SLS) posted quarterly Other financing activities of $66000.0 for Q1 2026, up 37.5% year-over-year from $48000.0 in Q1 2025, and up 100.3% quarter-over-quarter from -$21.9 million in Q4 2025.
Powered by 
Analysis
SELLAS Life Sciences (SLS) Other financing activities (2010 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Other financing activities for 13 consecutive years, with $66000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other financing activities rose 37.5% year-over-year to $66000.0; the TTM figure through Mar 2026 stood at $130000.0 (down 76.74% YoY), while the FY2025 annual figure was $112000.0, down 80.0% from the prior year.
- Other financing activities advanced to $66000.0 in Q1 2026 per SLS's latest filing, from -$21.9 million in the prior quarter.
- Across five years, Other financing activities topped out at $22.0 million in Q3 2025 and bottomed at -$21.9 million in Q4 2025.
- Historically, Other financing activities has averaged $74250.0 across 5 years, with a median of $47500.0 in 2022.
- On a YoY basis, Other financing activities climbed as much as 4226.57% in 2025 and fell as far as 2191600.0% in 2025.
- SELLAS Life Sciences' Other financing activities stood at $38000.0 in 2022, then sank by 63.16% to $14000.0 in 2023, then sank by 92.86% to $1000.0 in 2024, then sank by 2191600.0% to -$21.9 million in 2025, then jumped by 100.3% to $66000.0 in 2026.
- Business Quant data shows SLS's Other financing activities at $66000.0 in Q1 2026, -$21.9 million in Q4 2025, and $22.0 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn |
| 10 | SELLAS Life Sciences | 2.62 Bn | 2.62 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 100,000.00 |
| Mar 31, 2026 | 44.10 Mn |
| Dec 31, 2025 | 29.02 Mn |
| Sep 30, 2025 | 17.32 Mn |
| Jun 30, 2025 | 4.21 Mn |
| Mar 31, 2025 | 503,000.00 |
| Dec 31, 2024 | 1,000.00 |
| Sep 30, 2024 | 155,000.00 |
| Jun 30, 2024 | 353,000.00 |
| Mar 31, 2024 | 51,000.00 |
| Sep 30, 2023 | 54,000.00 |
| Mar 31, 2023 | 53,000.00 |
| Sep 30, 2022 | 38,000.00 |
| Mar 31, 2022 | 47,000.00 |
| Dec 31, 2021 | 50,000.00 |
| Sep 30, 2021 | 2,000.00 |
| Jun 30, 2021 | 17,000.00 |
| Mar 31, 2021 | 3.00 Mn |
| Dec 31, 2020 | 8.53 Mn |
| Mar 31, 2020 | 4,000.00 |